Bintrafusp alfa
- Generic Name
- Bintrafusp alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918149-01-5
- Unique Ingredient Identifier
- NW9K8C1JN3
- Background
Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).
- Associated Conditions
- -
- Associated Therapies
- -
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Phase 1
Recruiting
- Conditions
- Urothelial CancerGenitourinary CancerUrogenital NeoplasmsBladder CancerUrogenital Cancer
- Interventions
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT04235777
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath